JP2008536808A5 - - Google Patents

Download PDF

Info

Publication number
JP2008536808A5
JP2008536808A5 JP2007558176A JP2007558176A JP2008536808A5 JP 2008536808 A5 JP2008536808 A5 JP 2008536808A5 JP 2007558176 A JP2007558176 A JP 2007558176A JP 2007558176 A JP2007558176 A JP 2007558176A JP 2008536808 A5 JP2008536808 A5 JP 2008536808A5
Authority
JP
Japan
Prior art keywords
cell
sod
progesterone receptor
agent
modulates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007558176A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008536808A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/007253 external-priority patent/WO2006096404A2/en
Publication of JP2008536808A publication Critical patent/JP2008536808A/ja
Publication of JP2008536808A5 publication Critical patent/JP2008536808A5/ja
Pending legal-status Critical Current

Links

JP2007558176A 2005-03-04 2006-03-01 プロゲステロン受容体による神経変性疾患の調節 Pending JP2008536808A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65863005P 2005-03-04 2005-03-04
PCT/US2006/007253 WO2006096404A2 (en) 2005-03-04 2006-03-01 Treatment of amyotrophic lateral sclerosis with norethindrone and anal0gues

Publications (2)

Publication Number Publication Date
JP2008536808A JP2008536808A (ja) 2008-09-11
JP2008536808A5 true JP2008536808A5 (enExample) 2009-09-17

Family

ID=36825491

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007558176A Pending JP2008536808A (ja) 2005-03-04 2006-03-01 プロゲステロン受容体による神経変性疾患の調節

Country Status (7)

Country Link
US (2) US20060205704A1 (enExample)
EP (1) EP1861107A2 (enExample)
JP (1) JP2008536808A (enExample)
CN (1) CN101232888A (enExample)
AU (1) AU2006220918A1 (enExample)
CA (1) CA2600064A1 (enExample)
WO (1) WO2006096404A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101184493A (zh) * 2005-03-04 2008-05-21 阿尔斯根公司 用乙胺嘧啶及类似物治疗肌萎缩性侧索硬化
US20100028360A1 (en) * 2008-07-26 2010-02-04 Craig Stephen Atwood Methods for the modulation of brain progestagen signaling in the prevention and treatment of neurological disorders and neurodegenerative diseases
EP2320912B1 (en) * 2008-08-05 2015-01-14 University College Cork-National University of Ireland, Cork Treatment of retinal degeneration
US9446051B2 (en) 2009-10-19 2016-09-20 The Population Council, Inc. Neuroprotection and myelin repair using nestorone®
BR112012009306A2 (pt) * 2009-10-19 2016-06-07 Population Coucil Inc método para regeneração de mielina em um paciente
CA2836388A1 (en) * 2012-12-21 2014-06-21 The Population Council, Inc. Neuroprotection and myelin repair using st-1435

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916910A (en) * 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US20050019915A1 (en) * 2001-06-21 2005-01-27 Bennett C. Frank Antisense modulation of superoxide dismutase 1, soluble expression
EP1611238B1 (en) * 2003-02-26 2009-06-17 The John Hopkins University Glutamate transport modulatory compounds and methods
CN101184493A (zh) * 2005-03-04 2008-05-21 阿尔斯根公司 用乙胺嘧啶及类似物治疗肌萎缩性侧索硬化

Similar Documents

Publication Publication Date Title
NO2020004I1 (no) Larotrektinib og/eller farmasøytisk akseptable salter derav, særlig larotrektinibsulfat inkludert larotrektinibhydrogensulfat
IL200272A (en) Drugs containing progesterone for use in preventing premature birth and subsequent birth, and using this progesterone in the preparation of preparations for prevention of early onset and subsequent birth.
JP2008013542A5 (enExample)
EP2395834A4 (en) Sodium nitrite-containing pharmaceutical compositions
JP2010514554A5 (enExample)
JP2010535151A5 (enExample)
MX2022003132A (es) Composiciones de corticoesteroides administradas oralmente.
IL193702A (en) Pharmaceutical preparation containing human embryonic stem cells, methods of manufacture and use thereof
SG10201608214SA (en) Methods for cell phasing and placement in dynamic array architecture and implementation of the same
IL195470A0 (en) Antibodies as t cell receptor mimics, methods of production and uses thereof
JP2007527914A5 (enExample)
IL192374A0 (en) Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
GB0622457D0 (en) Improvements in and relating to external neurostimulation
TWI348162B (en) Memory cell structure and method of manufacturing the same, and mram cell structure
GB0704797D0 (en) Membrane structures and their production and use
JP2011516606A5 (enExample)
PL2049097T3 (pl) Kompozycja i sposób wiązania aldehydu octowego w żołądku
EP2152860A4 (en) PEPTIDE-RELATED CELLULAR MATRIX MATERIAL FOR STEM CELLS AND METHODS OF USE THEREOF
ATE536865T1 (de) Sublinguale brausetablette aus progesteron zusammen mit cyclodextrin
WO2009100262A3 (en) Oral care methods and systems
JP2008531710A5 (enExample)
PL2839836T3 (pl) Probiotyki do zastosowania przy redukowaniu objawów choroby układu oddechowego
DE602007012536D1 (de) Brennstoffzelle, brennstoffzellenstapel und herstellungsverfahren dafür
TWD137077S1 (zh) 燃料電池之計量閥
IL179884A0 (en) Fuel cells, micro-fuel cells and methods for the production thereof